In recent years, ICIs have been a promising therapy for malignancies.[8] Anti-PD-1/PD-L1 monoclonal antibodies have been extensively studied in different type of cancers.[3] The common side effects are reported as pneumonitis, hepatitis, endocrinopathies, dermatologic toxicity, gastrointestinal toxicity, and myositis.[9] Recently, the rare irAEs such as cardiovascular toxicity has been reported frequently.[9,10] The incidence of the ICI-associated myocarditis ranges from 0.09% to 1.14%, but the fatality rate is as high as 50% with monotherapy and 67% with combination immunotherapy.[10]. The gene discussed is PDCD1; the disease is endocrine system disorder.